The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

A new study published in Physiology & Behavior uncovers significant sensory implications of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), medications commonly prescribed for weight loss and ...

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven <a target=_ ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

GLP1-based obesity medicines, such as Ozempic and Wegovy, have surged in popularity and become the subject of intense public debate.

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

Well-organised crime entities - like Guzman and his Sinaloa cartel at one end, and our local outlaw motorcycle gangs at the other - secretly mark containers carrying the drugs using their own code, so ...